通过共享决策 (IMPACT SDM) 改善关狭窄患者的治疗决策研究:为集群随机阶段结试验的研究协议
Karen Sepucha1,2, Sammy Elmariah3, K D Valentine4,5
1Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA, USA.
Trials
|December 19, 2024
概括
正在研究共享决策 (SDM) 工具和培训,以改善严重大动脉狭窄患者的治疗选择,这些患者在跨导管大动脉置换 (TAVR) 和外科大动脉置换 (SAVR) 之间进行选择. 影响SDM研究评估了他们的有效性和实施.
科学领域:
- 心脏病学 心脏病学
- 医疗保健服务研究 医疗服务研究
- 实施科学 实施科学
背景情况:
- 分享决策 (SDM) 建议严重的大动脉狭窄患者在跨导管大动脉置换 (TAVR) 和外科大动脉置换 (SAVR) 之间做出决定.
- 患者决策辅助工具 (DA) 和SDM培训可以改善SDM,但它们的实施是有限的.
- 影响SDM研究解决了需要改善SDM和决策质量在这个患者群体.
研究的目的:
- 确定DA和临床医生SDM培训在实现SDM和改善大动脉置换决策质量的有效性.
- 评估DA的覆盖范围和SDM培训的采用.
- 探索影响有效性和实施的患者,临床医生和临床水平机制.
主要方法:
- 一个混合型II有效性-实施研究,使用一个集群随机化,分批分阶试验跨越8个美国站点.
- 患者在访问前和之后进行了调查;临床医生在访问后进行了调查.
- 追踪DA的覆盖范围和培训采用情况,与临床医生采访有关实施障碍和促进者的采访.
主要成果:
- 这个部分不在所提供的摘要中.
结论:
- 影响SDM研究将提供证据,证明干预措施在改善SDM和决策质量方面的有效性.
- 该研究旨在确定SDM实施的障碍和促进因素,以指导未来的努力.
更多相关视频
13:48Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound
Published on: April 21, 2023
1.4K
06:51Author Spotlight: Development of a Minimally Invasive Large-Animal Model for Reliable and Reproducible Cardiovascular Research
Published on: October 20, 2023
964
相关概念视频
Mitral Stenosis III: Medical Management
539
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
539
Atherosclerosis III: Management
747
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
747
